Abionic SA

Abionic is a Swiss medtech company based in Lausanne, focused on rapid diagnostics to support early clinical decision making. We have developed the abioSCOPE, a near-patient testing platform using nanofluidic technology, and a test measuring Pancreatic Stone Protein (PSP), a biomarker for early sepsis detection. Our solution is designed to provide actionable results within minutes, directly at the point of care. Abionic works closely with clinicians across Europe and the US to generate robust clinical evidence, with a strong focus on emergency and critical care settings where early identification of sepsis remains a key challenge.

Approach to Healthcare:

Our approach is very much clinician-driven. We focus on areas where there is still significant diagnostic uncertainty and where earlier decision making can change patient trajectories. In sepsis, the challenge is not only detecting infection but doing so early enough to act appropriately.

We work closely with emergency and critical care teams to understand real-world workflows, particularly in high-pressure environments like the Emergency Department. The goal is not to replace clinical judgment, but to provide an additional, reliable signal that helps clinicians prioritise patients more confidently at triage and in the first hours of care.

Impact of Products/Services on Healthcare:

In the ED, one of the key challenges is distinguishing patients with early infection from those with sterile inflammation, especially when clinical signs are still non-specific. This often leads either to delayed diagnosis or to precautionary overuse of antibiotics.

PSP has shown the ability to rise earlier than traditional biomarkers and to be less influenced by non-infectious inflammation. Used at triage, it can help identify patients at higher risk of sepsis earlier, while also supporting rule-in strategies in patients who may otherwise appear low risk (e.g. low qSOFA).

In practice, this can support faster escalation when needed, and more confident clinical decision making in the first hours of care.

Innovation:

Our innovation is both technological and clinical. On the technology side, the abioSCOPE uses a nanofluidic platform enabling rapid, quantitative results from a small sample directly at the bedside.

On the clinical side, we have focused on building evidence in challenging populations such as ED patients, burn patients, and trauma, where traditional biomarkers are often limited. More recently, we have expanded PSP use to the pediatric population following IVDR certification.

We are also working on simplifying the workflow further, with the next generation of our test aiming to be fully ready-to-use with minimal handling steps, which is particularly relevant for ED settings.

Future Direction:

Our priority is to further establish PSP in the Emergency Department, particularly in the UK where there is a strong focus on early triage and patient flow. We are currently working on generating prospective interventional data to better demonstrate the clinical impact of PSP-guided decision making at admission. More broadly, our objective is to support earlier and more precise identification of patients at risk of sepsis, ultimately helping clinicians make more confident decisions at the point where it matters most.